DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Essential Tremor - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Essential Tremor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Tremor) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Essential Tremor Overview
- Therapeutics Development
- Pipeline Products for Essential Tremor - Overview
- Pipeline Products for Essential Tremor - Comparative Analysis
- Essential Tremor - Therapeutics under Development by Companies
- Essential Tremor - Therapeutics under Investigation by Universities/Institutes
- Essential Tremor Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Essential Tremor - Products under Development by Companies
- Essential Tremor - Products under Investigation by Universities/Institutes
- Essential Tremor - Companies Involved in Therapeutics Development
- Merz GmbH & Co. KGaA
- Neurocrine Biosciences, Inc.
- Sage Therapeutics, Inc.
For more information visit http://www.researchandmarkets.com/research/rtkwj2/essential_tremor
